Literature DB >> 6297387

Pharmacokinetics of cefotiam in normal humans.

F D Daschner, K A Hemmer, P Offermann, J Slanicka.   

Abstract

Doses of 0.5, 1.0, and 2.0 g of cefotiam were infused intravenously over a 15-min period in a crossover fashion to eight volunteers. Doses of 1.0 and 2.0 g were infused intravenously over periods of 30 and 60 min in a double crossover fashion to another eight volunteers. Serum concentrations fell rapidly from peak levels between 30 and 170 micrograms/ml at the end of the infusion to less than 1.0 micrograms/ml within 6 h after all regimens. The terminal half-life in plasma varied between 0.6 and 1.1 h. The slopes of the time-concentration curves with the different regimens showed different half-life data. The urinary excretion of cefotiam was mostly completed within 4 h of the beginning of drug administration. The pharmacokinetics of cefotiam were dose dependent. With the 2-g dose, the peak plasma concentrations and the values for the area under the curve were more than twice the values observed with 1 g; decreasing values of plasma clearance were observed with higher doses. Injection of cefotiam caused no immediate discomfort or reaction at the infusion site.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6297387      PMCID: PMC185700          DOI: 10.1128/AAC.22.6.958

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice.

Authors:  T Iwahi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

2.  Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice.

Authors:  T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

3.  In vitro and in vivo morphological response of Klebsiella pneumoniae to cefotiam and cefazolin.

Authors:  M Nakao; T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

4.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

5.  Cefoperazone and cefotiam--two new cephalosporins: an in-vitro comparison.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1981-04       Impact factor: 5.790

  5 in total
  8 in total

Review 1.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Pharmacokinetics of cefotiam in humans.

Authors:  M C Rouan; J B Lecaillon; J Guibert; J Modai; J P Schoeller
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

4.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Cefotiam susceptibility testing criteria.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

Authors:  A M Brisson; A Bryskier; L Millerioux; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.

Authors:  K Konishi; Y Ozawa
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of cefotiam.

Authors:  J M Brogard; F Jehl; B Willemin; A M Lamalle; J F Blickle; H Monteil
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.